Navigation Links
Help at hand for RRMS patients

A revolutionary research study hints at the evidence that COPAXONE? (glatiramer acetate injection) may offer protection from axonal injury and induced neuronal metabolic recovery in patients with relapsing remitting multiple sclerosis (RRMS). //

COPAXONE? (glatiramer acetate injection) is a selective MHC class II modulator. COPAXONE? is indicated for the reduction of the frequency of relapses in relapsing remitting multiple sclerosis. The most common side effects of COPAXONE? are redness, pain, swelling, itching, or a lump at the site of injection, weakness, infection, pain, nausea, joint pain, anxiety, and muscle stiffness.

The research study which was a pilot study comprises 18 RRMS patients using brain imaging techniques. It was found that COPAXONE? produced significant increases in n-acetylaspartate/creatine (NAA/Cr) ratio, an indicator of neuron and axon integrity, compared to four untreated control patients after one year of treatment. This increase was maintained at two years of follow-up. Additionally, patients treated with COPAXONE? showed a significant 50 percent reduction in relapses compared to baseline (p<0.001) while relapse rate in the untreated group remained unchanged.

“The increases in NAA/Cr ratios with COPAXONE? suggested sustained beneficial effects on cerebral axonal recovery. We believe this indicates a potential for improved electrical conduction pathways in the brain, supporting the emerging concept that, centrally, COPAXONE? may be acting as a neuroprotective agent,” said Omar Khan, M.D., associate professor of neurology and director of experimental therapeutics/clinical research, Multiple Sclerosis Center, Wayne State University. “This data is of critical significance because axonal transection is a well-known feature of active MS lesions and represents an irreversible stage of the disease process,” said Dr. Khan.

Twenty-two treatment-na?ve RRMS patients were included in the study. Baseline neu
'"/>




Page: 1 2

Related medicine news :

1. HIV infected patients can travel safely abroad
2. New vaccine helps allergy and asthma patients
3. Doctors operate upon patients in candlelight- latest from the quake scene
4. New vaccine helps allergy and asthma patients
5. Are cancer patients being taken for a ride?
6. Alternative medicine more popular among HIV positive patients
7. ATG useful in transplant patients as substitute for steroids
8. Antidepressants come in handy for patients on treatment for hepatitis, cancers and multiple sclerosis
9. Distraction therapy found very effective in postoperative patients
10. Cancer patients turning to Internet for information
11. Helping stroke patients to recover balance
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Help hand for RRMS patients

Breaking Medicine Technology:Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3Disrupting a destructive duo 3A U of T Mississauga researchers inhibit cancer proteins 9634 1Disrupting a destructive duo 3A U of T Mississauga researchers inhibit cancer proteins 9634 2Ochsner and Rouses Markets Partner for Choose Healthy Initiative 54965 1Ochsner and Rouses Markets Partner for Choose Healthy Initiative 54965 2Ochsner and Rouses Markets Partner for Choose Healthy Initiative 54965 3Nostrils Compete to Relay Key Fragrance 54963 1Nostrils Compete to Relay Key Fragrance 54963 2